Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study

BACKGROUND: The phase 3 CLEAR study demonstrated statistically significantly improved efficacy with lenvatinib plus pembrolizumab versus sunitinib, including progression‐free survival and overall survival, in patients with previously untreated advanced renal cell carcinoma. This subset analysis inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Eto, Masatoshi, Takagi, Toshio, Kimura, Go, Fukasawa, Satoshi, Tamada, Satoshi, Miura, Yuji, Oya, Mototsugu, Sassa, Naoto, Anai, Satoshi, Nozawa, Masahiro, Sakai, Hideki, Perini, Rodolfo, Yusa, Wataru, Ikezawa, Hiroki, Narita, Tomoyuki, Tomita, Yoshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067092/
https://www.ncbi.nlm.nih.gov/pubmed/36457273
http://dx.doi.org/10.1002/cam4.5483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067092/
https://www.ncbi.nlm.nih.gov/pubmed/36457273
http://dx.doi.org/10.1002/cam4.5483

Ejemplares similares